it's been a softly softly launch so it's not going to be...

it's been a softly softly launch so it's not going to be gangbusters initially, anyone expecting that to drive share price will be disappointed in my view.

initial australian sales will be solid but not spectacular. this launch is all about ironing out the strategy and testing what works in the marketplace and user feedback. management is not about the drop a release saying we sold X number of units.

more likely gains will come when we get fda approval, new innovations, a national tv ad campaign and commercial tie-ups with chemist and insurance distributors. This sell off has had much to do with the US malaise and one big sale of one million, which pretty much appears to have gone to friendly hands. Those driving the stock have laid low during this uncertainty and the low volume attests to nervous nellies quitting profits/losses.

I'm not getting suckered here. M health is here and growing. The Australian 'hold' recommendation the other day summed it up ... data on 100,000 users not yet priced into the company and m health a growing area that will attract predators who will pay a premium to aquire the technology and the data base.